1. For subjects in Cohort A: previous therapy for more than 48 hours with any parenteral antibiotic with activity against S. aureus within 72 hours of positive blood culture results. 
2. For subjects in Cohort B: previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence. 
3. Previous episode of S. aureus bacteremia within 3 months. 
4. Known left-sided endocarditis or prosthetic heart valve. 
5. Osteomyelitis or prosthetic joint infection except new onset nonhardware-associated vertebral osteomyelitis. 
6. History of any hypersensitivity or allergic reaction to any β-lactam antibacterial agent. 
7. Evidence of significant hepatic, hematologic, or immunologic impairment. 
8. Pregnant or nursing females.       
    

NCT01701219_exc_T1
Observation
Cohort A
NCT01701219_exc_T3
Procedure
therapy
NCT01701219_exc_T5
Temporal
previous
NCT01701219_exc_T6
Temporal
for more than 48 hours
NCT01701219_exc_T7
Drug
parenteral antibiotic with activity against S. aureus
NCT01701219_exc_T8
Qualifier
with activity against S. aureus
NCT01701219_exc_T9
Observation
S. aureus
NCT01701219_exc_T10
Temporal
within 72 hours of positive blood culture results
NCT01701219_exc_T11
Reference_point
positive blood culture results
NCT01701219_exc_T12
Procedure
blood culture
NCT01701219_exc_T13
Value
positive results
NCT01701219_exc_T14
Observation
Cohort B
NCT01701219_exc_T16
Scope
previous therapy for more than 48 hours with any parenteral antibiotic with activity against S. aureus within 72 hours of positive blood culture results.
NCT01701219_exc_T17
Temporal
previous
NCT01701219_exc_T18
Procedure
therapy
NCT01701219_exc_T20
Temporal
for more than 48 hours
NCT01701219_exc_T21
Drug
parenteral antibiotic with activity against MRSA
NCT01701219_exc_T22
Qualifier
parenteral
NCT01701219_exc_T23
Qualifier
parenteral
NCT01701219_exc_T24
Qualifier
with activity against MRSA
NCT01701219_exc_T25
Observation
MRSA
NCT01701219_exc_T26
Drug
vancomycin
NCT01701219_exc_T27
Negation
except
NCT01701219_exc_T28
Drug
daptomycin
NCT01701219_exc_T29
Temporal
within 72 hours of positive blood culture results
NCT01701219_exc_T30
Reference_point
positive blood culture results
NCT01701219_exc_T31
Value
positive results
NCT01701219_exc_T32
Procedure
blood culture
NCT01701219_exc_T33
Scope
except vancomycin and/or daptomycin
NCT01701219_exc_T34
Condition
S. aureus bacteremia
NCT01701219_exc_T35
Observation
S. aureus
NCT01701219_exc_T36
Qualifier
S. aureus
NCT01701219_exc_T37
Temporal
within 3 months
NCT01701219_exc_T38
Condition
left-sided endocarditis
NCT01701219_exc_T39
Qualifier
left-sided
NCT01701219_exc_T40
Device
prosthetic heart valve
NCT01701219_exc_T41
Condition
Osteomyelitis
NCT01701219_exc_T42
Condition
prosthetic joint infection
NCT01701219_exc_T43
Temporal
new onset
NCT01701219_exc_T44
Qualifier
nonhardware-associated
NCT01701219_exc_T45
Condition
vertebral osteomyelitis
NCT01701219_exc_T46
Negation
except
NCT01701219_exc_T47
Condition
hypersensitivity
NCT01701219_exc_T48
Condition
allergic reaction
NCT01701219_exc_T49
Drug
β-lactam antibacterial agent
NCT01701219_exc_T50
Scope
hypersensitivity or allergic reaction
NCT01701219_exc_T51
Observation
History
NCT01701219_exc_T52
Condition
hepatic impairment
NCT01701219_exc_T53
Condition
immunologic impairment
NCT01701219_exc_T54
Condition
hematologic impairment
NCT01701219_exc_T55
Condition
Pregnant
NCT01701219_exc_T56
Condition
nursing
NCT01701219_exc_T57
Person
females
NCT01701219_exc_T58
Scope
previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence